Previous 10 | Next 10 |
MP0533: Phase 1 trial of MP0533 for AML ongoing; initial recruitment is progressing well, and site expansion is ongoing; initial clinical results on track for Q4 2023 MP0317: Highest dose cohort (Q3W, 10mg/kg) now enrolling; clinical update at ASCO Radio DARPin T...
2023-04-20 02:08:08 ET Summary Molecular Partners is priced below its net enterprise value, meaning Wall Street is placing no real value on its drugs under development. Management believes it has enough capital on hand for drug trials plus R&D until 2026. The almost comple...
Targeted radionuclide delivery platform strengthened by new safety and mechanistic data Data includes review of high tumor penetration potential of DARPins and reduced kidney accumulation via DARPin engineering New findings will be shared on April 18, 2023, at the American Associa...
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 04, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that the shareholders of th...
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 13, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today published the invitation to ...
2023-03-10 13:05:22 ET Molecular Partners AG (MOLN) Q4 2022 Earnings Conference Call March 10, 2023 08:00 ET Company Participants Seth Lewis - Senior Vice President, Investor Relations Patrick Amstutz - Chief Executive Officer Robert Hendriks - Senior Vice Presid...
2023-03-10 13:05:10 ET The following slide deck was published by Molecular Partners AG in conjunction with their 2022 Q4 earnings call. For further details see: Molecular Partners AG 2022 Q4 - Results - Earnings Call Presentation
2023-03-09 16:05:03 ET Molecular Partners press release ( NASDAQ: MOLN ): FY GAAP EPS of $3.54 misses by $0.52 . Revenue of $189.6M misses by $5.3M . For further details see: Molecular Partners GAAP EPS of $3.54 misses by $0.52, revenue of $189.6M misses ...
Research & Development Highlights: Initiated Phase 1 study of MP0533, a novel tri-specific T-cell engager for the treatment of acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS) Presented preclinical data supporting the unique design and mechanism of MP053...
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will issue a press release summarizing its ...
News, Short Squeeze, Breakout and More Instantly...
Molecular Partners AG Company Name:
MOLN Stock Symbol:
NASDAQ Market:
Molecular Partners AG Website:
2024-07-07 11:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 3.5% to $130.78 on volume of 504,910,586 shares Nikola Corporation (NKLA) fell 31.5% to $0.3296 on volume of 265,124,783 shares SMX (Security Matters) Public Limited Company (SMX) rose 35.1% to $0.1608 o...
A look at the top 10 most actives in the United States SMX (Security Matters) Public Limited Company (SMX) rose 43.0% to $0.1702 on volume of 99,421,591 shares NVIDIA Corporation (NVDA) rose 3.5% to $140.3486 on volume of 71,277,917 shares MGO Global Inc. (MGOL) rose 222.9% to $1.48 on vo...